ProPhase Labs, Inc. (PRPH)
| Previous Close | 5.16 |
| Open | 5.17 |
| Bid | 4.99 x 100 |
| Ask | 5.19 x 100 |
| Day's Range | 5.05 - 5.46 |
| 52 Week Range | 4.05 - 9.94 |
| Volume | |
| Avg. Volume | 51,338 |
| Market Cap | 91.309M |
| Beta (5Y Monthly) | -0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 24, 2022 |
| 1y Target Est | 21.00 |
- GlobeNewswire
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase’s business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: ProPhase Labs Advances Cancer Treatment with Project ZenQ-AI - ProPhase Labs h
GlobeNewswireProPhase Labs Unveils Project ZenQ-AI
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was
ZacksStrength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
